Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe [0.03%]
新型TKI/ICI联合治疗在转移性肾细胞癌中的作用？或许吧
L Meza,P G Bergerot,N Agarwal et al.
L Meza et al.
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial [0.03%]
意大利TOSCA三期随机试验中3个月或6个月辅助化疗的总生存率
F Petrelli,E Rulli,R Labianca et al.
F Petrelli et al.
Background: Oxaliplatin-based adjuvant chemotherapy is the standard treatment of high-risk colon cancer (CC). A shorter duration (3 months) can achieve a similar outcome [in terms of relapse-free survival (RFS)] to a long...
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial [0.03%]
靶向成纤维细胞激活蛋白的CAR T细胞局部递送在胸膜间皮瘤患者中安全：FAPME一期临床试验首次报告
S Hiltbrunner,C Britschgi,P Schuberth et al.
S Hiltbrunner et al.
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) [0.03%]
新辅助紫杉醇/奥拉帕利对比紫杉醇/卡铂在HER2阴性乳腺癌和同源重组缺陷患者中的疗效（GeparOLA研究）
P A Fasching,T Link,J Hauke et al.
P A Fasching et al.
Background: The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2 mutation] is...
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 [0.03%]
癌症患者和感染了SARS-CoV-2的肿瘤科医务人员的血清转化研究
A Marra,D Generali,P Zagami et al.
A Marra et al.
Background: Patients with cancer have high risk for severe complications and poor outcome to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease [coronavirus disease 2019 (COVID-19)]. Almost all s...
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy [0.03%]
嵌合抗原受体(CAR)T细胞治疗的副作用管理
M-L Schubert,M Schmitt,L Wang et al.
M-L Schubert et al.
Chimeric antigen receptor (CAR) T cells directed against the B-cell marker CD19 are currently changing the landscape for treatment of patients with refractory and/or relapsed B-cell malignancies. Due to the nature of CAR T cells as living d...
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial [0.03%]
结构染色体不稳定表型作为三阴性乳腺癌卡铂反应生物标志物的评估：TNT试验
O Sipos,H Tovey,J Quist et al.
O Sipos et al.
Background: In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal instabilit...
Data protection and research in the European Union: a major step forward, with a step back [0.03%]
欧盟的数据保护与研究：前进一步，后退半步
P G Casali,M Vyas;European Society for Medical Oncology (ESMO)
P G Casali
Cautionary tails [0.03%]
值得警惕的三大尾部风险
J C Del Paggio,I F Tannock
J C Del Paggio
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance [0.03%]
BRCA基因中复原突变的荟萃分析鉴定出DNA末端连接修复机制驱动治疗抵抗的特征信号
L Tobalina,J Armenia,E Irving et al.
L Tobalina et al.
Background: Germline mutations in the BRCA1 or BRCA2 (BRCA) genes predispose to hereditary breast and ovarian cancer and, mostly in the case of BRCA2, are also prevalent in cases of pancreatic and prostate malignancies. T...